{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T07:46:08Z","timestamp":1782459968908,"version":"3.54.5"},"reference-count":24,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,13]],"date-time":"2024-09-13T00:00:00Z","timestamp":1726185600000},"content-version":"vor","delay-in-days":135,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Prevention of Alzheimer's Disease"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.14283\/jpad.2024.60","type":"journal-article","created":{"date-parts":[[2024,3,13]],"date-time":"2024-03-13T12:27:57Z","timestamp":1710332877000},"page":"537-548","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["At-home Administration of Gantenerumab by Care Partners to People with Early Alzheimer's Disease: Feasibility, Safety and Pharmacodynamic Impact"],"prefix":"10.1016","volume":"11","author":[{"given":"Frank G.","family":"Boess","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.A.","family":"Scelsi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Grimmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.J.","family":"Perry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Tonietto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Klein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Hofmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Salami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Wojtowicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.J.","family":"Lansdall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Lane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.A.","family":"Kerchner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.S.","family":"Doody","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.14283\/jpad.2024.60_bib1","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa2100708","article-title":"Donanemab in early Alzheimer's disease","volume":"384","author":"Mintun","year":"2021","journal-title":"New England Journal of Medicine"},{"key":"10.14283\/jpad.2024.60_bib2","doi-asserted-by":"crossref","DOI":"10.1001\/jama.2023.13239","article-title":"Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial","author":"Sims","year":"2023","journal-title":"JAMA"},{"key":"10.14283\/jpad.2024.60_bib3","first-page":"197","article-title":"Two randomized phase 3 studies of aducanumab in early Alzheimer's disease","volume":"9","author":"Budd Haeberlein","year":"2022","journal-title":"J Prev Alzheimers Dis"},{"key":"10.14283\/jpad.2024.60_bib4","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2212948","article-title":"Lecanemab in early Alzheimer's disease","volume":"388","author":"van Dyck","year":"2023","journal-title":"New England Journal of Medicine"},{"key":"10.14283\/jpad.2024.60_bib5","doi-asserted-by":"crossref","first-page":"49","DOI":"10.3233\/JAD-2011-110977","article-title":"Gantenerumab: a novel human anti-A\u03b2 antibody demonstrates sustained cerebral amyloid-\u03b2 binding and elicits cell-mediated removal of human amyloid-\u03b2","volume":"28","author":"Bohrmann","year":"2012","journal-title":"Journal of Alzheimer's disease: JAD"},{"key":"10.14283\/jpad.2024.60_bib6","doi-asserted-by":"crossref","first-page":"3233","DOI":"10.1021\/acschemneuro.0c00364","article-title":"Computational investigation of gantenerumab and crenezumab recognition of A\u03b2 fibrils in Alzheimer's disease brain tissue","volume":"11","author":"Chen","year":"2020","journal-title":"ACS Chem Neurosci"},{"key":"10.14283\/jpad.2024.60_bib7","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1001\/archneurol.2011.1538","article-title":"Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab","volume":"69","author":"Ostrowitzki","year":"2012","journal-title":"Arch Neurol"},{"key":"10.14283\/jpad.2024.60_bib8","first-page":"3","article-title":"Thirty-six-month amyloid positron emission tomography results show continued reduction in amyloid burden with subcutaneous gantenerumab","volume":"8","author":"Klein","year":"2021","journal-title":"J Prev Alzheimers Dis"},{"key":"10.14283\/jpad.2024.60_bib9","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1186\/s13195-022-01110-8","article-title":"Gantenerumab: an anti-amyloid monoclonal antibody with potential disease-modifying effects in early Alzheimer's disease","volume":"14","author":"Bateman","year":"2022","journal-title":"Alzheimers Res Ther"},{"key":"10.14283\/jpad.2024.60_bib10","first-page":"18621876","article-title":"Two phase 3 trials of gantenerumab in early Alzheimer's disease","volume":"389.20","author":"Bateman","year":"2023","journal-title":"New England Journal of Medicine"},{"key":"10.14283\/jpad.2024.60_bib11","series-title":"Prescribing information","author":"Enbrel (etanercept)","year":"2012"},{"key":"10.14283\/jpad.2024.60_bib12","series-title":"Prescribing information","author":"Betaseron (interferon beta-1b)","year":"2016"},{"key":"10.14283\/jpad.2024.60_bib13","series-title":"Prescribing information","author":"Hemlibra (emicizumab-kxwh)","year":"2017"},{"key":"10.14283\/jpad.2024.60_bib14","series-title":"Prescribing information","author":"Humalog (insulin lispro injection)","year":"2013"},{"key":"10.14283\/jpad.2024.60_bib15","doi-asserted-by":"crossref","first-page":"801","DOI":"10.2147\/CEOR.S317687","article-title":"Payer Perspectives on Intravenous versus Subcutaneous Administration of Drugs","volume":"13","author":"Epstein","year":"2021","journal-title":"ClinicoEconomics and Outcomes Research"},{"key":"10.14283\/jpad.2024.60_bib16","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.jalz.2011.03.008","article-title":"The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease","volume":"7","author":"Albert","year":"2011","journal-title":"Alzheimer's & dementia: the journal of the Alzheimer's Association"},{"key":"10.14283\/jpad.2024.60_bib17","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","article-title":"The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease","volume":"7","author":"McKhann","year":"2011","journal-title":"Alzheimer's & dementia: the journal of the Alzheimer's Association"},{"key":"10.14283\/jpad.2024.60_bib18","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1212\/WNL.43.11.2412-a","article-title":"The Clinical Dementia Rating (CDR): current version and scoring rules","volume":"43","author":"Morris","year":"1993","journal-title":"Neurology"},{"key":"10.14283\/jpad.2024.60_bib19","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/0022-3956(75)90026-6","article-title":"\u201cMini-mental state\u201d. A practical method for grading the cognitive state of patients for the clinician","volume":"12","author":"Folstein","year":"1975","journal-title":"Journal of psychiatric research"},{"key":"10.14283\/jpad.2024.60_bib20","series-title":"Prescribing information","author":"Neuraceq (Florbetaben)","year":"2014"},{"key":"10.14283\/jpad.2024.60_bib21","series-title":"Summary of Product Characteristics","author":"Neuraceq (Florbetaben)","year":"2014"},{"issue":"2","key":"10.14283\/jpad.2024.60_bib22","doi-asserted-by":"crossref","first-page":"351","DOI":"10.2214\/ajr.149.2.351","article-title":"MR signal abnormalities at 1.5 T in Alzheimer's dementia and normal aging","volume":"149","author":"Fazekas","year":"1987","journal-title":"AJR Am J Roentgenol"},{"key":"10.14283\/jpad.2024.60_bib23","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.2147\/PPA.S108489","article-title":"Validation of a treatment satisfaction questionnaire in non-Hodgkin lymphoma: assessing the change from intravenous to subcutaneous administration of rituximab","volume":"10","author":"Theodore-Oklota","year":"2016","journal-title":"Patient Preference and Adherence"},{"key":"10.14283\/jpad.2024.60_bib24","doi-asserted-by":"crossref","unstructured":"Schwab D, Jolivet S, Gibiansky L, Lott D, Systemic exposures of gantenerumab: An integrated population pharmacokinetics analysis across multiple clinical studies. Poster number #83055, presented at the 2023 Alzheimer's Association International Conference; 16\u201320 July, 2023; Amsterdam, Netherlands.","DOI":"10.1002\/alz.083055"}],"container-title":["The Journal of Prevention of Alzheimer's Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2274580724000463?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2274580724000463?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T23:34:59Z","timestamp":1736465699000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2274580724000463"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":24,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["S2274580724000463"],"URL":"https:\/\/doi.org\/10.14283\/jpad.2024.60","relation":{},"ISSN":["2274-5807"],"issn-type":[{"value":"2274-5807","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"At-home Administration of Gantenerumab by Care Partners to People with Early Alzheimer's Disease: Feasibility, Safety and Pharmacodynamic Impact","name":"articletitle","label":"Article Title"},{"value":"The Journal of Prevention of Alzheimer's Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.14283\/jpad.2024.60","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2024 THE AUTHORS. Published by Elsevier Masson SAS on behalf of SERDI Publisher. Published by Elsevier Masson SAS","name":"copyright","label":"Copyright"}]}}